Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2, 2009. The report details a strategic collaboration with Human Genome Sciences, Inc. (HGS) regarding the development of BENLYSTA (belimumab), an investigational drug for systemic lupus erythematosus (SLE). The filing announces positive results from the second of two pivotal Phase 3 clinical trials.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures for GSK or HGS. The document focuses exclusively on clinical trial outcomes and regulatory milestones.
Material Changes and Clinical Results
The primary material change is the successful completion of the primary efficacy endpoint in the BLISS-76 Phase 3 trial, confirming results from the earlier BLISS-52 trial. Key findings include:
- Primary Endpoint Met: Belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate versus placebo at Week 52 (p=0.021).
- Response Rates: 43.2% for 10 mg/kg belimumab, 40.6% for 1 mg/kg belimumab, and 33.8% for placebo.
- Safety Profile: The drug was generally well tolerated. Overall adverse event rates were comparable between treatment groups. Serious/severe adverse events occurred in 26.8% of belimumab patients vs. 24.0% of placebo patients.
- Study Scope: BLISS-76 randomized 819 patients across 136 sites in 19 countries. The study is ongoing for a total of 76 weeks, with additional data expected after the full period.
Guidance, Outlook, and Risks
Outlook and Next Steps:
- GSK and HGS plan to submit marketing applications in the United States, Europe, and other regions in the first half of 2010.
- Full 76-week data will be presented at a scientific meeting, likely in the first half of 2010.
- BENLYSTA is positioned as the first new approved drug in decades for SLE.
- Under the August 2006 agreement, GSK and HGS share equally in Phase 3/4 development costs, sales, marketing expenses, and profits.
- Belimumab remains an investigational drug; approval is not guaranteed.
- Forward-looking statements are subject to risks including regulatory uncertainty, clinical trial outcomes, and patent protection issues.
- HGS faces risks related to its unproven business model, substantial indebtedness, and dependence on collaborators.
Investor Verification Checklist
- Verify the timeline for Biologics License Application (BLA) submissions in the U.S. and Marketing Authorization Applications in Europe for H1 2010.
- Monitor the release of full 76-week data from the BLISS-76 study to confirm long-term efficacy and safety.
- Review the financial impact of the 50/50 cost and profit-sharing agreement between GSK and HGS on future earnings.
- Assess regulatory feedback from the FDA and EMA following the submission of marketing applications.
- Track the commercialization strategy for BENLYSTA given the lack of new SLE treatments in 50 years.